Development of a Noninvasive Glucose Monitor

Information

  • Research Project
  • 6552262
  • ApplicationId
    6552262
  • Core Project Number
    R44DK057362
  • Full Project Number
    2R44DK057362-02
  • Serial Number
    57362
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/2000 - 24 years ago
  • Project End Date
    6/30/2004 - 20 years ago
  • Program Officer Name
    SWAIN, AMY L
  • Budget Start Date
    7/15/2002 - 22 years ago
  • Budget End Date
    6/30/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    2
  • Suffix
  • Award Notice Date
    7/15/2002 - 22 years ago
Organizations

Development of a Noninvasive Glucose Monitor

DESCRIPTION (provided by applicant): The goal of this project is to develop a portable, noninvasive, personal blood glucose monitor. VivaScan has developed and successfully tested a laboratory prototype instrument based on the Optical Bridge TM (OB) method. The OB uniquely nulls out the background absorption of the sample, overcoming the major problem of optical blood glucose measurements. Our successful Phase I diabetic patient study produced 96% of the measurement data in the clinically acceptable A and B zones of the Clarke error grid. The aims for Phase II include: 1) enhance electronics with microcontroller; 2) redesign and miniaturize the optics and device mechanics; 3) investigate the use of optical interference filters for acousto-optical tunable filters (AOTF) substitutes; 4) replace expensive AOTF, used for wavelength generation, with less expensive devices; 5) further enhance the glucose measurement algorithms; and 6) build four portable devices and test their performance with patients. Overall, the goal of the proposed work is to extend our laboratory prototype system to a patient oriented device, with improved accuracy, portability, ease of operation and affordability. Subsequent FDA approval of a practical portable in-home blood glucose monitor will be sought, allowing diabetic patients to noninvasively and painlessly monitor their glucose levels throughout the day. PROPOSED COMMERCIAL APPLICATIONS: Our market analysis suggests that from 500,000 to 4.4 million diabetic individuals could use a non-invasive glucose monitor. The global market would increase these projections by a factor of 2 or more.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    500399
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:500399\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    VIVASCAN CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    Worcester
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    016052627
  • Organization District
    UNITED STATES